MMRGlobal Launches Licensed Service Offerings and Commences Patent License Discussions With Hospitals and Nursing Associations

LOS ANGELES, CA--(Marketwire - Nov 28, 2012) -   MMRGlobal, Inc. (OTCQB: MMRF) ("MMR") today announced that the Company has agreed to the terms of patent license agreements with three EMR and PHR vendors and has already begun making licensed services available to more than 30,000 physician accounts belonging to one of the licensees. The Company is also in the process of licensing its patented Personal Health Records technologies and other intellectual property with hospital networks, purchasing syndicates and trade associations representing thousands of hospitals, clinics and other healthcare providers in Illinois, Arizona, New Jersey Louisiana and Pennsylvania. MMR's health IT patent portfolio includes five patents issued by the United States Patent and Trademark Office including U.S. Patent Nos. 8,121,855; 8,117,646; 8,117,045; 8,301,466 and 8,321,240, as well as hundreds of additional pending claims involving provisioning of Personal Health Records and other claims and features included in Electronic Medical Records systems. MMR has an estimated 360 issued and/or pending claims in thirteen countries pertaining to the use and deployment of online Personal Health Records and other Electronic Medical Records systems, many originating as far back as 2005 (collectively, "MMR's IP"). The Company is also in talks with nursing associations regarding the use of its MyMedicalRecords Personal Health Record in the care of more than 50,000 patients. The MMR IP is believed to impact Stage 2 Meaningful Use requirements for deployment of Personal Health Records by 2014.

MMR has launched a marketing, media and trade press campaign which has reached thousands of hospitals, physician group practices and other healthcare professionals regarding purchasing the Company's products and services, and/or to discuss licensing and sub-licensing opportunities for the Company's IP globally. MMR's primary objective is to utilize its patents and other intellectual property to sell its untethered standardized PHR for the benefit of patients and their family. The MyMedicalRecords PHR can be deployed by any healthcare professional regardless of current systems including any EMR in use by a provider. The Company is also pursuing strategic relationships with vendors to cost-effectively facilitate the licensing of its IP to satisfy Meaningful Use requirements under the HITECH Act to offer PHRs. The Company received its latest patent from the USPTO, 8,231,240, yesterday.

According to Robert H. Lorsch, MMRGlobal CEO, "Over the past several months, MMR has held road shows, webinars and one-on-one meetings throughout the United States with strategic development partner Nihilent Technologies to explain the benefits of the MMR IP to healthcare executives, hospital administrators, payors and other industry professionals. The Company as the owner of its patents is working to monetize the intellectual property which it created by selling products and services that utilize its patents, unlike other organizations known as patent trolls. Our technologies allow documents, images and voicemail messages to be securely transmitted in and out of PHRs and other eHealth systems using a variety of methods, including fax, voice, file upload, email and other forms of messaging and do not rely on any specific Electronic Medical Record system to populate a PHR or portions of an EMR."

According to Jonathan A. Wiesman, Vice President at Nihilent, "As a result of the MMR patent portfolio, awareness of MMR's products and services is significant. The MMR IP opens the doors to opportunities with the largest players in healthcare. No matter the size, they are seeing the value of MMR's untethered service offering for their hospital, practice or as an employee/patient benefit. MMR also represents a cost-effective solution to provide PHRs as required under Meaningful Use."

About MMRGlobal, Inc.

MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. The Company's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. Through its merger with Favrille, Inc. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId™/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc. visit View demos and video tutorials of the Company's products and services at

About Nihilent
Nihilent is a global consulting and solutions integration company using a holistic and systems approach to problem solving. Headquartered in Pune, India, Nihilent's executive team has over 350 person-years of experience in international consulting, IT outsourcing and IT services. Nihilent has made major intellectual contributions to the development of IT around the world and its operations span North America, Europe, Africa, Middle East and Asia. Nihilent's mission 'Change for Performance' encapsulates its commitment to make change happen systemically in terms of people, process, technology and knowledge for achieving sustained performance for its clients. For more information, please visit

Forward-Looking Statements
All statements in this press release that are not strictly historical in nature, including, without limitation, licenses, potential intellectual property enforcement actions, infringement claims, or litigation, future performance, management's expectations, beliefs, intentions, estimates or projections, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as "need," "possibility," "potential," "intend," "offer," "development," "if," "negotiate," "when," "begun," "believe," "achieve," "will," "estimate," "expect," "maintain," "plan," and "continue," or the negative of these words. Actual outcomes of intellectual property enforcement actions, infringement claims, litigation or licensing transactions, results of operations and the timing of selected events may differ materially from the results predicted, and any reported results should not be considered as an indication of future performance. Such statements are necessarily based on assumptions and estimates and are subject to various risks and uncertainties, including those relating to the possible invalidity of the underlying assumptions and estimates and possible changes or developments in economic, business, industry, market, legal and regulatory circumstances and conditions and actions taken or omitted to be taken by third parties, including customers, suppliers, business partners, potential licensees, competitors and legislative, judicial and other governmental authorities and officials. Factors that could cause or contribute to such differences include, but are not limited to: unexpected outcomes with respect to intellectual property enforcement actions, claims of intellectual property infringement and general intellectual property litigation; our ability to maintain, develop, monetize and protect our patent portfolio for both the Company's health IT and biotechnology intellectual property assets in the U.S. and internationally; the timing of milestone payments in connection with licensing our intellectual property; our ability to establish and maintain strategic relationships; changes in our relationships with our licensees; the risk the Company's products are not adopted or viewed favorably by the healthcare community and consumer retail market; business prospects, results of operations or financial condition; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; the timing and volume of sales and installations; the length of sales cycles and the installation process; the market's acceptance of new product and service introductions; competitive product offerings and promotions; changes in government laws and regulations and future changes in tax legislation and initiatives in the healthcare industry; undetected errors in our products; the possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; risks related to a security breach by third parties; risks associated with recruitment and retention of key personnel; other litigation matters; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is providing this information as of the date of this release and, except as required by applicable law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Contact Information:


Michael Selsman
Public Communications Co.
(310) 922-7033